流感-新冠联合重组蛋白疫苗可诱导针对流感病毒和SARS-CoV-2感染的保护性免疫应答
研究将流感病毒血凝素(HA)蛋白与SARS-CoV-2刺突(S)蛋白配以AddaVax佐剂制成流感-新冠联合重组蛋白疫苗,在K18-hACE-2转基因小鼠中以初免-加强-加强方案肌内接种,再用致死剂量流感病毒或SARS-CoV-2攻击。结果显示联合疫苗通过防止体重下降和临床症状进展,保护小鼠抵御两种病毒攻击,其诱导的保护性免疫应答与单价流感或新冠重组蛋白疫苗相当。
要点
- 联合疫苗含流感HA与SARS-CoV-2 S蛋白,配以AddaVax佐剂。
- 联合疫苗可防止致死剂量流感病毒或SARS-CoV-2攻击后的体重下降和临床症状进展。
- 联合疫苗诱导的保护性免疫应答与单价流感或新冠重组蛋白疫苗相当。
核心结论
- 流感-新冠联合重组蛋白疫苗在预防流感和COVID-19感染方面显示出有效性。
研究设计与样本
- 研究开发含流感病毒血凝素(HA)蛋白和SARS-CoV-2刺突(S)蛋白并配以AddaVax佐剂的流感-新冠联合疫苗。
- K18-hACE-2转基因小鼠经肌内接种联合疫苗或单价流感(HA)或新冠(S)重组蛋白疫苗,采用初免-加强-加强方案,随后用致死剂量流感病毒或SARS-CoV-2攻击以评估疫苗效力。
主要发现
- 联合疫苗通过防止体重下降和临床症状进展,保护小鼠抵御流感病毒和SARS-CoV-2攻击。
- 联合疫苗诱导的保护性免疫应答与单价流感或新冠重组蛋白疫苗诱导的应答相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SARS-CoV-2 and Influenza viruses are both highly transmissible airborne viruses and causing high morbidity and mortality. Co-infection of these two viruses results in severe disease that have been observed when influenza and SARS-CoV-2 viruses cocirculated in the past three years, and vaccination is still the effective way to prevent these two diseases. However, influenza and COVID-19 vaccines are designed and manufactured in different platforms, all the individuals will need to get two shots in order to prevent those two severe respiratory diseases. Therefore, it is urgent to develop a Flu-COVID combo vaccine to provide an efficient way for receiving immunization against those two diseases. In this study, we developed a flu-COVID combo vaccine that includes both influenza virus haemagglutinin (HA) proteins and SARS-CoV-2 Spike (S) protein which formulated with AddaVax. K18-hACE-2 transgenic mice were intramuscularly vaccinated with either combo vaccine or mono Flu (HA) or COVID (S) recombinant protein vaccine in a prime-boost-boost regimen, and then were challenged with lethal doses of influenza virus or SARS-CoV-2 to evaluate vaccine efficacy. The results showed that Flu-COVID combo vaccine protected mice from both Influenza and SARS-CoV-2 challenge by preventing body weight loss and clinical signs progression. The protective immune responses elicited by Flu-COVID combo vaccine were equivalent to those elicited by mono flu or COVID recombinant protein vaccines. In conclusion, our study highlights the effectiveness of the FLU-COVID combo recombinant protein vaccine in preventing both influenza and COVID-19 infections.
引用
- Huang Y, Shi H, Forgacs D, et al. Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection. Vaccine. 2024. PMID: 38296701. doi:10.1016/j.vaccine.2023.12.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。